Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
Lilly's Jaypirca recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia across all lines of therapy
What Medicare Part D patients need to know about accessing Foundayo and Zepbound for weight management
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Lilly's Jaypirca significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
Zepbound and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
FDA approves Lilly's EBGLYSS® for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non?communicable Disease and Chronic Conditions
Lilly's oral GLP-1 Foundayo delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
Homerun Resources Inc. Advances Solar Glass Project Financing with Letter of Intent from Leading European Project Finance Bank for up to 170 Million Euros
Transition Metals Commences 2026 Exploration Program at Pike Warden Epithermal Gold-Silver and Porphyry Copper Project, Yukon
Infill Drilling Significantly Widens and Extends Near Surface Gold Mineralisation at Gemdale Gold's Pontio Gold Project, Finland
SAGA Metals Reports Assays from R-0055 to R-0057 with Intercepts Including 53.72% Fe2O3, 8.24% TiO2, 0.377% V2O5 from 2026 Drilling at Radar Critical Minerals Project in Labrador
